NEW DELHI: India’s Health Ministry warned on Tuesday of the unregulated use of weight-loss drugs, as cheap generic versions of blockbuster diabetes medications such as Ozempic entered the market following patent expiry. The patent on semaglutide, the active ingredient in weight-loss drugs such as Ozempic and Wegovy, expired on March 20 in India, allowing local pharmaceutical companies to produce their own versions and sell them at a fraction of the original price.

Indian generic drugmakers launch a price war against Novo Nordisk’s GLP-1 brands, Ozempic and WeGovy.

India’s health ministry warned Tuesday of the risks of unregulated use of weight-loss drugs, as low-cost generic versions hit the market, stepping up inspections and enforcement…

India intensifies regulatory measures on weight loss drugs to prevent unauthorized sales and ensure safe medical use.

NEW DELHI: India’s Health Ministry warned on Tuesday of the unregulated use of weight-loss drugs, as cheap generic versions of blockbuster diabetes medications such as Ozempic…